The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe

Molecular Pharmaceutics

Volumn 6, Issue 4, 2009, Pages 1216-1227

  Chang, Jae H ^a   Yoo, Phillip ^b   Lee, Theresa ^a   Klopf, Wendy ^a   Takao, Denise ^a  

^a Non Clinical Safety   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Ezetimibe; Glucuronidation; Microsomes; Mycophenolic acid; Permeability; pH; Raloxifene; UGT

Indexed keywords

EZETIMIBE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; MYCOPHENOLIC ACID; RALOXIFENE;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG GLUCURONIDATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER MICROSOME; MEMBRANE PERMEABILITY; PH; PRIORITY JOURNAL;

AZETIDINES; CHROMATOGRAPHY, LIQUID; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSOMES, LIVER; MYCOPHENOLIC ACID; RALOXIFENE; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 68249092793     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900065b     Document Type: Article

References (46)

1. Radominska-Pandya, A.; Czernik, P. J.; Little, J. M.; Battaglia, E.; Mackenzie, P. I. Structural and functional studies of UDPglucuronosyltransferases. Drug Metab Rev. 1999, 31 (4), 817-899
2. Cappiello, M.; Giuliani, L.; Pacifici, G. M. Distribution of UDPglucuronosyltransferase and its endogenous substrate uridine 5′-diphosphoglucuronic acid in human tissues. Eur. J. Clin. Pharmacol. 1991, 41 (4), 345-350
3. Tukey, R. H.; Strassburg, C. P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 581-616. (Pubitemid 30340694)
4. Miners, J. O.; Knights, K. M.; Houston, J. B.; Mackenzie, P. I. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. 2006, 71 (11), 1531-1539
5. Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; Peterkin, V.; Koup, J. R.; Ball, S. E. Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 2004, 32 (11), 1201-1208
6. Goodman, L. S.; Hardman, J. G.; Limbird, L. E.; Gilman, A. G. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed.; McGraw-Hill Medical Pub. Division: New York, 2001; p xxvii, 2148 pp, [1] folded leaf of plate.
7. Fisher, M. B.; Labissiere, G. The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Curr. Drug Metab. 2007, 8 (7), 694-699 (Pubitemid 47578117)
8. Shepherd, S. R.; Baird, S. J.; Hallinan, T.; Burchell, B. An investigation of the transverse topology of bilirubin UDPglucuronosyltransferase in rat hepatic endoplasmic reticulum. Biochem. J. 1989, 259 (2), 617-620 (Pubitemid 19111705)
9. Yokota, H.; Yuasa, A.; Sato, R. Topological disposition of UDP-glucuronyltransferase in rat liver microsomes. J. Biochem. 1992,112 (2), 192-196
10. Berry, C.; Stellon, A.; Hallinan, T. Guinea pig liver microsomal UDP-glucuronyltransferase: compartmented or phospholipidconstrained. Biochim. Biophys. Acta 1975, 403 (2), 335-344
11. Bingham, P.; Berry, C.; Hallinan, T. Compartmentation of uridine diphosphate glucuronosyltransferase: effect of uridine diphosphate N-acetylglucosamine on the apparent V of glucuronidation [proceedings]. Biochem. Soc. Trans. 1978, 6 (1), 178-180 (Pubitemid 8325960)
12. Dutton, G. J., Glucuronidation of drugs and other compounds. ed.; CRC Press: Boca Raton, Fla., 1980; 268 pp.
13. Kilford, P. J.; Stringer, R.; Sohal, B.; Houston, J. B.; Galetin, A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab. Dispos. 2009, 37 (1), 82-89
14. Fisher, M. B.; Campanale, K.; Ackermann, B. L.; VandenBranden, M.; Wrighton, S. A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab. Dispos. 2000, 28 (5), 560-566
15. Engtrakul, J. J.; Foti, R. S.; Strelevitz, T. J.; Fisher, M. B. Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab. Dispos. 2005, 33 (11), 1621-1627
16. Starostin, A. V.; Butan, R.; Borisenko, V.; James, D. A.; Wenschuh, H.; Sansom, M. S.; Woolley, G. A. An anion-selective analogue of the channel-forming peptide alamethicin. Biochemistry 1999, 38 (19), 6144-6150 (Pubitemid 129514906)
17. Hall, J. E.; Vodyanoy, I.; Balasubramanian, T. M.; Marshall, G. R. Alamethicin. A rich model for channel behavior. Biophys. J. 1984, 45 (1), 233-247
18. Meissner, G.; Allen, R. Evidence for two types of rat liver microsomes with differing permeability to glucose and other small molecules. J. Biol. Chem. 1981, 256 (12), 6413-6422
19. Nilsson, R.; Peterson, E.; Dallner, G. Permeability of microsomal membranes isolated from rat liver. J. Cell Biol. 1973, 56 (3), 762-776
20. Lizak, B.; Csala, M.; Benedetti, A.; Banhegyi, G. The translocon and the non-specific transport of small molecules in the endoplasmic reticulum (Review). Mol. Membr. Biol. 2008, 25 (2), 95-101. (Pubitemid 351320500)
21. Howland, R. D.; Bohm, L. D. Possible multiple binding sites for o-aminophenol on uridine diphosphate glucuronyltransferase. Biochem. J. 1977, 163 (1), 125-131
22. Vessey, D. A.; Zakim, D. Regulation of microsomal enzymes by phospholipids. II. Acitvation of hepatic uridine diphosphateglucuronyltransferase. J. Biol. Chem. 1971, 246 (15), 4649-4656
23. Basu, N. K.; Ciotti, M.; Hwang, M. S.; Kole, L.; Mitra, P. S.; Cho, J. W.; Owens, I. S. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J. Biol. Chem. 2004, 279 (2), 1429-1441
24. Chang, J. H.; Benet, L. Z. Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol. Pharmaceutics 2005, 2 (5), 428-434
25. Bowalgaha, K.; Miners, J. O. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br. J. Clin. Pharmacol. 2001, 52 (5), 605-609
26. Shipkova, M.; Strassburg, C. P.; Braun, F.; Streit, F.; Grone, H. J.; Armstrong, V. W.; Tukey, R. H.; Oellerich, M.; Wieland, E. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br. J. Pharmacol. 2001, 132 (5), 1027-1034
27. Jeong, E. J.; Liu, Y.; Lin, H.; Hu, M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab. Dispos. 2005, 33 (6), 785-794
28. Kemp, D. C.; Fan, P. W.; Stevens, J. C. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 2002, 30 (6), 694-700.
29. Ghosal, A.; Hapangama, N.; Yuan, Y.; Achanfuo-Yeboah, J.; Iannucci, R.; Chowdhury, S.; Alton, K.; Patrick, J. E.; Zbaida, S. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab. Dispos. 2004, 32 (3), 314-320 (Pubitemid 38263889)
30. Turgeon, D.; Carrier, J. S.; Chouinard, S.; Belanger, A. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab. Dispos. 2003, 31 (5), 670-676 (Pubitemid 36444177)
31. Hwang, C.; Sinskey, A. J.; Lodish, H. F. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 1992, 257 (5076), 1496-1502
32. Meldolesi, J.; Pozzan, T. The endoplasmic reticulum Ca2+ store: a view from the lumen. Trends Biochem. Sci. 1998, 23 (1), 10-14 (Pubitemid 28093986)
33. Lin, Y.; Lu, P.; Tang, C.; Mei, Q.; Sandig, G.; Rodrigues, A. D.; Rushmore, T. H.; Shou, M. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab. Dispos. 2001, 29 (4 Pt 1), 368-374 (Pubitemid 32275548)
34. Uchaipichat, V.; Galetin, A.; Houston, J. B.; Mackenzie, P. I.; Williams, J. A.; Miners, J. O. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol. Pharmacol. 2008, 74 (4), 1152-1162
35. Soars, M. G.; Ring, B. J.; Wrighton, S. A. The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. Drug Metab. Dispos. 2003, 31 (6), 762-767 (Pubitemid 36617665)
36. Radominska, A.; Little, J. M.; Lehman, P. A.; Samokyszyn, V.; Rios, G. R.; King, C. D.; Green, M. D.; Tephly, T. R. Glucuronidation of retinoids by rat recombinant UDP: glucuronosyltransferase 1.1 (bilirubin UGT). Drug Metab. Dispos. 1997, 25 (7), 889-892
37. Fujiwara, R.; Nakajima, M.; Yamanaka, H.; Katoh, M.; Yokoi, T. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab. Dispos. 2008, 36 (2), 361-367 (Pubitemid 351185749)
38. Fujiwara, R.; Nakajima, M.; Yamanaka, H.; Nakamura, A.; Katoh, M.; Ikushiro, S.; Sakaki, T.; Yokoi, T. Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab. Dispos. 2007, 35 (5), 747-757 (Pubitemid 46641545)
39. Operana, T. N.; Tukey, R. H. Oligomerization of the UDPglucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and coimmunoprecipitation. J. Biol. Chem. 2007, 282 (7), 4821-4829
40. Borisenko, V.; Sansom, M. S.; Woolley, G. A. Protonation of lysine residues inverts cation/anion selectivity in a model channel. Biophys. J. 2000, 78 (3), 1335-1348
41. Green, W. N.; Andersen, O. S. Surface charges and ion channel function. Annu. Rev. Physiol. 1991, 53, 341-359
42. Quagliariello, E.; Palmieri, F.; Prezioso, G.; Klingenberg, M. Kinetics of succinate uptake by rat-liver mitochondria. FEBS Lett. 1969, 4 (4), 251-254.
43. Ryu, S.; Liu, B.; Qin, F. Low pH potentiates both capsaicin binding and channel gating of VR1 receptors. J. Gen. Physiol. 2003, 122 (1), 45-61. (Pubitemid 36859131)
44. Lin, J. H.; Wong, B. K. Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr. Drug Metab. 2002, 3 (6), 623-646
45. Rowland, A.; Gaganis, P.; Elliot, D. J.; Mackenzie, P. I.; Knights, K. M.; Miners, J. O. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J. Pharmacol. Exp. Ther. 2007, 321 (1), 137-147
46. Rowland, A.; Knights, K. M.; Mackenzie, P. I.; Miners, J. O. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab. Dispos. 2008, 36 (6), 1056-1062